ORIGINAL ARTICLE
Prognostic potential of PRMT5 and DSG2 proteins in pre-malignant cervical lesions
1
Department of Histology and Embryology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
2
Department of Anatomy, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
Submission date: 2023-11-24
Final revision date: 2024-03-28
Acceptance date: 2024-04-07
Publication date: 2024-08-12
Corresponding author
Veronika Mešťanová
Department of Histology and Embryology, Jessenius Faculty of Medicine , Comenius University in Bratislava, Malá Hora 4, 036 01 Martin, Slovakia
Department of Histology and Embryology, Jessenius Faculty of Medicine , Comenius University in Bratislava, Malá Hora 4, 036 01 Martin, Slovakia
Pol J Pathol 2024;75(2):115-125
KEYWORDS
TOPICS
ABSTRACT
Precancerous cervical lesions are metaplastic alterations of epithelial cells of the cervix, eventually developing into cervical cancer. Despite primary and secondary prevention, the burden of cervical cancer remains high globally. Protein arginine methyltransferases (PRMT) represent post-translational modifications that interact with multiple signalling pathways, playing a role in epithelial-mesenchymal transition. In complex with desmoglein-2 (DSG2), a cell adhesion protein, both participate in the progression of dysplastic changes with potential malignant development.
The presented study was performed on archival paraffin-embedded blocks from adult women. The studied samples were categorised into low-grade and high-grade intraepithelial lesions. Immunohistochemical analysis was used to observe subcellular localisation, immunoreaction intensity, and percentage of PRMT5- and DSG2-expressing cells, followed by statistical analysis.
Preliminary results identified statistically significant differences between the expression and subcellular localisation of proteins in question in low-grade and high-grade squamous intraepithelial lesions. The primary goal of the presented study is to perceive the involvement of PRMT5 and DSG2 in the initiation and progression of cervical lesions.
Our observations indicate the potential of the assessed proteins as prognostic markers. However, further studies of PRMT5 and DSG2 are required to provide greater insight into cervical carcinogenesis.
The presented study was performed on archival paraffin-embedded blocks from adult women. The studied samples were categorised into low-grade and high-grade intraepithelial lesions. Immunohistochemical analysis was used to observe subcellular localisation, immunoreaction intensity, and percentage of PRMT5- and DSG2-expressing cells, followed by statistical analysis.
Preliminary results identified statistically significant differences between the expression and subcellular localisation of proteins in question in low-grade and high-grade squamous intraepithelial lesions. The primary goal of the presented study is to perceive the involvement of PRMT5 and DSG2 in the initiation and progression of cervical lesions.
Our observations indicate the potential of the assessed proteins as prognostic markers. However, further studies of PRMT5 and DSG2 are required to provide greater insight into cervical carcinogenesis.
REFERENCES (40)
1.
Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet 2019; 393: 169-182.
2.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
3.
Zhang S, Xu H, Zhang L, et al. Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res 2020; 32: 720-728.
4.
Ephrem Dibisa K, Tamiru Dinka M, Mekonen Moti L, et al. Precancerous lesion of the cervix and associated factors among women of West Wollega, West Ethiopia, 2022. Cancer Control 2022; 29:10732748221117900.
5.
Yuan Y, Nie H. Protein arginine methyltransferase 5: a potential cancer therapeutic target. Cell Oncol (Dordr) 2021; 44: 33-34.
6.
Jiang Y, Yuan Y, Chen M, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics 2021; 11: 9162-9176.
7.
Gao J, Liu R, Feng D, et al. Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition. Cell Death Differ 2021; 28: 2818-2836.
8.
Shailesh H, Zakaria ZZ, Baiocchi R, et al. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget 2018; 9: 36705-36718.
9.
Hegazy M, Perl AL, Svoboda SA, et al. Desmosomal cadherins in health and disease. Ann Rev Pathol 2022; 17: 47-72.
10.
Zhou BX, Li Y. Significance of desmoglein-2 on cell malignant behaviors via mediating MAPK signaling in cervical cancer. Kaohsiung J Med Sci 2020; 36: 336-343.
11.
Xiao W, Chen X, Liu L, et al. Role of protein arginine methyltransferase 5 in human cancers. Biomed Pharmacother 2019; 114: 108790.
12.
Chen Y, Shao X, Zhao X, et al. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms. Biomed Pharmacother 2021; 144: 112252.
13.
Motolani A, Martin M, Sun M, et al. The Structure and functions of PRMT5 in human diseases. Life (Basel) 2021; 11: 1074.
14.
Inoue M, Okamoto K, Terashima A, et al. Arginine methylation controls the strength of c-family cytokine signaling in T cell maintenance. Nat Immunol 2018; 19: 1265-1276.
15.
Tanaka Y, Nagai Y, Okumura M, et al. PRMT5 is required for T cell survival and proliferation by maintaining cytokine signaling. Front Immunol 2020; 11: 621.
16.
Abe Y, Sano T, Tanaka N. The role of PRMT5 in immuno-oncology. Genes 2023; 14: 678.
17.
Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci 2015; 72: 2041-2059.
18.
Tan LY, Mintoff Ch, Johan MZ, et al. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget 2016; 7: 46492-46508.
19.
Kamekura R, Kolegraff KN, Nava P, et al. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Oncogene 2014; 33: 4531-4536.
20.
Barber AG, Castillo-Martin M, Bonal DM, et al. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One 2014; 9: 98786.
21.
Cai F, Zhu Q, Miao Y, et al. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res and Clin Oncol 2017; 143: 59-69.
22.
Ma X, Zhan L, Sun S, et al. Identification of PRMT5 as a diagnosis biomarker for cervical cancer by bioinformatics analysis. J Women´s Health Dev 2022; 5: 240-246.
23.
Dong SH, Wang X, Tian SC, et al. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo. Pharmazie 2018; 73: 269-273.
24.
Kumar B, Yadav A, Brown NV, et al. Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely asso- ciated with p16-status. Oncotarget 2017; 8: 14847-14859.
25.
Li M, Yang J, Liu K, et al. p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis. J Cancer 2020; 11: 1457-1467.
26.
Fan Z, He L, Li M, et al. Targeting methyltransferase PRMTretards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription. Neoplasia 2020; 22: 617-629.
27.
Yang D, Liang T, Gu Y, et al. Protein N-arginine methyltransferase 5 promotes the tumor progression and radioresistance of nasopharyngeal carcinoma. Oncol Rep 2016; 35: 1703-1710.
28.
Amano Y, Matsubara D, Yoshimoto T, et al. Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition. Pathol Int 2018; 68: 359-366.
29.
Wang N, Yan H, Wu D, et al. PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma. Cell Death Dis 2020; 11: 864.
30.
Wu Y, Wang Z, Zhang J, et al. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol 2017; 39: 1010428317695917.
31.
Shailesh H, Siveen KS, Sif S. Protein arginine methyltransferase 5 (PRMT5) activates WNT/-catenin signaling in breast cancer cells via epigenetic silencing of DKK1 and DKK3. J Cell Mol Med 2021; 25: 1583-1600.
32.
Yang F, Wang J, Ren HY, et al. Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression. Tumour Biol 2015; 36: 5901-5911.
33.
Wang Z, Kong J, Wu Y, et al. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Res Treat 2018; 168: 531-542.
34.
Shilo K, Wu X, Sharma S, et al. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagn Pathol 2013; 8: 201.
35.
Zhang S, Ma Y, Hu X, et al. Targeting PRMT5/Akt signaling axis prevents human lung cancer cell growth. J. Cell Mol. Med 2019; 23: 1333-1342.
36.
Alazawi WOF, Morris LS, Stanley MA, et al. Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Virchows Arch 2003; 443: 51-56.
37.
Zhao M, Huang W, Zou S, et al. A Five-genes-based prognostic signature for cervical cancer overall survival prediction. Int J Genomics 2020; 2020: 8347639.
38.
Qin S, Liao Y, Du Q, et al. DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer. Cancer Cell Int 2020; 20: 206.
39.
Chang PH, Chen MC, Tsai YP, et al. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proc Natl Acad Sci U S A. 2021; 118: e2014408118.
40.
Abudula A, Rouzi N, Xu L, et al. Tissue-based metabolomics reveals potential biomarkers for cervical carcinoma and HPV infection. Bosn J Basic Med Sci 2020; 20: 78-87.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
